ImmunoGen's CEO Discusses F4Q12 Results - Earnings Call Transcript

ImmunoGen, Inc. (OKS)

Q4 2012 Earnings Call

August 3, 2012, 08:00 am ET


Carol Hausner - Executive Director, IR & Corporate Communications

Dan Junius - President & CEO

Greg Perry - EVP & CFO

Jim O'Leary - VP & CMO


Thomas Wei - Jefferies

Adnan Butt - RBC Capital Markets

Mara Goldstein - Cantor Fitzgerald

John Sonnier - William Blair

Ling Wang - Summer Street Partners

Boris Peaker - Oppenheimer

Cory Kasimov - JPMorgan

Yale Jen - Roth Capital Partners

David Miller - Biotech Stock Research



Good day and welcome everyone to this ImmunoGen, fourth quarter fiscal year 2012 financial results conference call. Today’s call is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to the Executive Director, Investor Relations and Corporate Communications, Carol Hausner. Please go ahead.

Carol Hausner

Thank you. Good morning. At 6:30 am this morning, we issued a press release that summarizes our financial results for our fourth quarter and fiscal year ended June 30, 2012. I hope you have all had a chance to review it, if not; it’s available on our website.

During today’s call we will make forward-looking statements. Our actual results may differ materially from such statements. Descriptions of the risks and uncertainties associated with an investment in ImmunoGen are included in our SEC filings, which also can be accessed through our website.

In our call today, our Chief Executive Officer, Dan Junius, will provide an update on ImmunoGen and our Chief Financial Officer, Greg Perry, will discuss our financial results and guidance for our fiscal year 2013. We will then open the call to questions. Our Chief Medical Officer Dr. Jim O'Leary will be available for the question-and-answer session. Dan?

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

7 Stocks Under $10 Making Big Up Moves

Strong On High Relative Volume: Immunogen (IMGN)